Moderna’s Post

What's the power of unlocking the invisible college in pharma? 🔐 The concept of the 'Invisible College' is revolutionizing how pharma teams identify key opinion leaders. Learn about the transformative impact of revealing hidden connections: 🔗 https://hubs.la/Q02gYsb80

🌟 Great presentations by Yike Xie, Evgeniia Shcherbinina, Gayathri Narasimhan, and Angana Patel (who presented in place of Nadia Gul) during the WCMTM and AstraZeneca postdoc seminar in April! In this industry postdoc program, a PI from each organization joins forces with a shared postdoctoral researcher. Together they conduct a research project focused on innovation and health benefits. While presenting methodologies, results, and timelines, the postdocs also underscored a vital aspect: the invaluable access to both the university and the AstraZeneca labs, capabilities, and network. Pernille B. Laerkegaard Hansen who is Executive Director and Head of Bioscience Renal and CVRM at AstraZeneca, was one of the participants at the seminar: “The joint postdoc program is intended as a close collaboration allowing the researchers to work as one single team, although placed in different organizations and locations,” Pernille said. Learn more about the seminar and the ongoing projects at our website https://lnkd.in/dPBaXpgd #innovation #healthinnovation #lifescience #academy #industry #collaboration #astrazeneca #wcmtm #postdoc #

Last week, we achieved another important milestone for #TEHA's Life Sciences Community.    It was a pleasure to organize and moderate the roundtable discussion "Elevating Innovation in Life Sciences: Europe’s leading TTOs in the spotlight”, held at the wonderful facilities of Humanitas Research in Milan. This event marked a significant step in our journey though innovation in #LifeSciences, showcasing the pivotal role of technology transfer processes to bring innovation from bench to bedside. Many thanks to our speakers (Robert AL, MBA RTTP, Nunzio Gennaro Cifariello, E-MBA, Irene Fialka, Anji Miller Ph.D CLP RTTP, Paola Vella, Corrado Panzeri) and to the many leaders of research and innovation that participated in the discussion (Francesca Pasinelli, Fabio Terragni, Fabrizio Conicella, Vittoria Pavoncello, Emiliano Schena and many others).     Some of the key takeaways from the discussion:  - what pharma and biotech companies are really looking for is not just science, but rather a solution to a specific need. To be patient-centered, technology transfer offices (TTOs) should focus on finding solutions that can meet market demands and patients’ need. - Multidisciplinary strategies and diverse expertise are essential. Italian universities and TTOs should actively seek to educate and hire individuals with mixed scientific backgrounds, embracing multidisciplinary knowledge that spans various therapeutic areas.  - Despite progress such as the abolishment of the professors’ privilege, there are still many bureaucratic obstacles that continue to hinder the Italian competitiveness in the global arena of innovation. It is imperative to address these constraints, particularly at the public level, to accelerate the speed at which innovations enter the market.     We are very pleased to have created this opportunity for dialogue and to have highlighted the example of Humanitas as an Italian excellence in research and innovation.   #InnoTech #innovation #TechnologyTransfer 

A Catalyst for Change: How Biomedical & Clinical Research Adapted to the COVID-19 Pandemic The COVID-19 pandemic presented an unprecedented challenge for the world, and the biomedical and clinical research industry rose to the occasion with remarkable agility. Here at Scientia Nova (Pvt Ltd), we witnessed a significant shift in focus and collaboration: 1. Accelerated Research & Development: 🔹 Vaccine Development: The global research community embarked on a record-breaking sprint to develop safe and effective vaccines – a testament to international collaboration. 🔹 Repurposing Existing Drugs: Researchers explored the potential of existing medications for treating COVID-19 symptoms, accelerating treatment options. 🔹 Diagnostic Tools: The development and deployment of rapid and reliable diagnostic tests became a crucial tool for managing the outbreak. 2. Embracing Virtual Collaboration: 🔹 Virtual Trials: Clinical trials adopted virtual elements (e.g., telemedicine consultations) to ensure participant safety and maintain research progress. 🔹 Data Sharing: Open-source data platforms facilitated rapid research collaboration and knowledge exchange across borders. 🔹 Virtual Conferences & Events: The scientific community pivoted to virtual conferences, fostering continued communication and knowledge dissemination. 3. Prioritization & Resource Allocation: 🔹 Funding Surge: Governments and private donors significantly increased funding for COVID-19 research, accelerating critical projects. 🔹 Streamlined Regulations: Regulatory agencies adopted faster review processes for COVID-19 research proposals without compromising safety standards. 🔹 Repurposing Resources: Research labs and facilities redirected efforts towards COVID-19 research while maintaining essential ongoing projects. The Road Ahead 🛣 The lessons learned from the pandemic's impact on biomedical and clinical research offer valuable insights for the future. Collaboration, agility, and a focus on patient needs will continue to be cornerstones of successful research endeavors. Let us know your thoughts on how the pandemic has impacted the biomedical research industry ☑ To avail our services or for any queries, please reach out through either of the following platforms. Our team will reach out to you soon! 📧 contact@scientianova.co.uk 🆔 https://lnkd.in/dE6Es6u2 🌐 www.scientianova.co.uk #COVID19 #biomedicalresearch #clinicalresearch #researchresponse #collaboration #innovation #vaccines #diagnostics #clinicaltrials #pandemicpreparedness #researchmetrics #innovation #efficiency #impactauthorship #futureofmedicine #patientcare #drugdiscovery #researchskills #science #healthcare #researchtechnology #AI #bioinformatics #telemedicine #GCP #IRB #FDA #HIPAA #patientrights #researchintegrity #healthcare #clinicaltrials #medicine #surgery #research #pharmacy #publichealth #research #scientianova

Transform scientific research with Nobly Clinical Research Solution! 🚀   Facing the challenge of speeding up research project initiations, Nobly A/S and Turku University Hospital (Tyks) have revolutionized the process. What used to take months now takes days!   Discover the power of electronic authorization and streamlined processes that not only accelerate decision-making but also enhance project success rates.   Dive into the future of research efficiency in the article below.   #ScientificResearch #Innovation #ResearchEfficiency

ICYMI: Apply now for our fall fellowship! How can medicines be both profitable to develop and affordable for patients who need them? Join students, young professionals, and future biotech leaders in a guided program that answers this question and surveys the foundations of biomedical innovation and affordability. Learn from biotech leaders and meet like-minded peers during live lectures and discussions that unite lessons on investing, drug development, health economics, and public policy—led by leaders across the biotech ecosystem. Details and application below. https://lnkd.in/eegQpzav

I'll be at #SCOPESummit too! Looking forward to connecting with old and new friends next week and sharing more about our platforms at OmniScience. Please reach out if you'd like to connect! #clinicaldevelopment #clinicaltrials #biopharma #datascience #clinicaldata

Are breakthroughs in mRNA technology a template for R&I processes in Europe? Leading experts explore this question at the #HamburgScienceSummit: Plenary Table #4: The future of health: Medical breakthroughs made in Europe Iordanis (Danos) Arzimanoglou (former Program Manager Health and Biotechnology, European Innovation Council) Maria A. Blasco (Director, Spanish National Cancer Research Centre) Dr. Myriam Mendila (Chief Development Officer, CureVac N.V.) Vivienne Parry (Science journalist) Medical research is at a turning point. The COVID-19 crisis has shown that Europe is capable of efficient R&I processes, with the mRNA technology being the most prominent example. Part of the success story has been increased cross-sector collaboration between academics, medical companies, regulators, and financial incentives provided by government and private actors. At the same time, the crisis revealed barriers to innovation, such as poor availability and quality of health data, or problems in research and administrative infrastructures. This raises questions about the future of medical research in Europe: What breakthroughs can be expected from European medical researchers in the coming years? Is the COVID case a viable template for other R&I processes in Europe? And how can medical innovation contribute to Europe’s technological sovereignty without undermining global justice, particularly with regard to public health in the Global South? Please note: Anthony Hyman won't be able to join us at the panel. He will be repaced by Maria A. Blasco. The #HamburgScienceSummit is an annual conference that brings together scientists, policy-makers, business and think-tanks. Curious to learn more? Check out our website (link in our comment)! #euresearch #futurtech #technologicalsovereignty #publichealth #healthinnovation #hamburgsciencesummit #gesellschaftbessermachen

A Milestone in Austin’s Life Sciences Journey: BillionToOne’s Expansion Overnight successes are years in the making. BillionToOne has officially launched the construction of their new 220,000-square-foot facility in north Austin—a transformative step for the region's life sciences ecosystem. This isn’t just another groundbreaking moment; it’s the culmination of years of collaboration and vision between community leaders, industry pioneers, and key partners like Tarlton, STG Design, and White Construction. With BillionToOne’s cutting-edge "forever lab" set to process up to 6 million tests per year and create over 600 new jobs, this development further solidifies the Austin region’s position as a leader in precision diagnostics and the broader life sciences sector. Through collaborative efforts, we’ve created a region that attracts world-class companies like BillionToOne—companies that seek not just to do business, but to innovate and grow within our thriving ecosystem of talent and technology. As Austin grows, these life sciences investments pave the way for breakthroughs that will benefit both our community and global healthcare advancements. Learn more about this impactful project: https://lnkd.in/gb9GfGcy 

A graph or infographic visually representing the impact of treatment discontinuation on clinical trial outcomes. Are you facing challenges in accurately estimating treatment effects in your clinical trials due to treatment discontinuation? Traditional methods like MMRM and MI might be overlooking crucial factors. This research highlights the potential bias introduced by ignoring treatment discontinuation and proposes innovative MI models to address this issue. Want to learn more about how to improve the reliability of your trial results? Let's connect! #clinicaltrials #biostatistics #estimands #ICHE9 #drugdevelopment #medicalresearch #datascience Share your thoughts on handling treatment discontinuation in your clinical trials. Let's discuss how our approach can benefit your research. https://lnkd.in/g2aaaA2i